



SUPPLEMENTARY FIGURES


* $p < 0.01$



Supplementary Figure S1: DLD-1 cells were treated with α -mangostin, resveratrol, epigallocatechin-3-gallate, baccharin and drupanin (2, 5, 10 μ M) and/or rTRAIL (5 ng/ml) for 48 h. Data were obtained from 3 independent experiments. The cell viability of the control (0; DMSO alone) is indicated as 100%.



Supplementary Figure S2: TRAIL-sensitive DLD-1 and -resistant DLD-1 cells were treated with α -mangostin (2, 5, 7 μ M) for 48 h. Western blot analysis was performed to determine the expression of LC3B-II, with β -actin as an internal control.



Supplementary Figure S3: TRAIL-sensitive DLD-1 and -resistant DLD-1 cells were treated with α -mangostin (2, 5, 7, 10 μ M) for 48 h. Western blot analysis was performed to determine the expression of Ack1. β -Actin was used as the internal control.